Polydatin down-regulates the phosphorylation level of Creb and induces apoptosis in human breast cancer cell

Sijia Chen1☯, Jialong Tao1☯, Fengyun Zhong1☯, Yang Jiao2, Jiaying Xu2, Qiang Shen3, Haichao Wang4, Saijun Fan2*, Yusong Zhang1*

1 Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, P.R. China, 2 School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu, P.R. China, 3 Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 4 The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, New York, United States of America

☯ These authors contributed equally to this work.
* zhangyusong19@163.com (YZ); fansaijun36@163.com (SF)

Abstract

Polydatin (PD), a component isolated from Polygonum cuspidatum, has a number of biological functions. However, the antitumor activity of PD has been poorly investigated. In this study, the effect of PD on cell proliferation was evaluated by thiazolyl blue tetrazolium bromide assay. Cell cycle distribution and apoptosis were investigated by flow cytometry. The phosphorylation levels of panel of phosphor-kinases were detected by human phospho-kinase arrays. The expression of several proteins associated with cell cycle and apoptosis were analyzed by Western blot analysis. Results showed that PD effectively inhibited the growth of MDA-MB-231 and MCF-7 breast cancer cell lines. Cell cycle analysis demonstrated that PD induced S-phase cell cycle arrest. Human phosphor-kinase arrays showed that the phosphorylation level of cAMP response element-binding proteins (Creb) was down-regulated, and the results were further confirmed by Western blot analysis. Western blot analysis showed that the expression of protein of cyclin D1 decreased in a time- and dose-dependent manner. Results suggest that PD is a potential therapeutic natural compound.

Introduction

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females worldwide, with an estimated 1.7 million cases and 521,900 deaths in 2012. Breast cancer alone accounts for 25% of all cancer cases and 15% of all cancer death among females [1]. Advances in surgery, radiotherapy, hormonal therapy, and chemotherapy have improved the treatment outcome of breast cancer. However, more than 410,000 women still die from this disease every year [2]. To date, chemotherapy has become the most frequently used therapeutic strategy for breast cancer. Furthermore, the outcome of chemotherapy in
patients with advanced breast cancer is poor, thus highlighting the need for novel chemother-
apy agent.

As described previously[3], polydatin(PD) is a glycoside of resveratrol in which the glyco-
side group is bonded in the C-3 position and substitutes a hydroxyl group. (the chemical struc-
ture of PD is shown in Fig 1). This substitution leads to conformational changes in the
molecule, thus resulting in changes in its biological properties. PD is more efficiently absorbed
and more resistant to enzymatic oxidation than resveratrol and is soluble in hot water. In con-
trast to resveratrol, which penetrates cells passively, PD enters cells via an active mechanism
using glucose carriers. These properties provide PD with greater bioavailability than resvera-
trol. Previous studies have demonstrated the chemo-preventive and anticancer activities of res-
veratrol [4–13]. However, few previous studies have analyzed the effects of PD on human
cancer cells. In the current study, the effects of PD on the proliferation, cell cycle phase distri-
bution, and apoptosis of human breast cancer cell lines as well as potential underlying mecha-
nisms, were investigated.

Materials and methods

Chemicals

LKT Laboratories Inc. (St Paul, MN, USA) was the supplier of the PD (Catalog No. P5845)
used in this study. PD was dissolved in a stock solution of 10 mmol/l dimethysulfoxide
(DMSO) and was directly diluted in a medium to appropriate concentrations prior to the
experiments. Thiazolyl blue tetrazolium bromide (MTT; Catalog No. M2128) was purchased
from Sigma-Aldrich (St. Louis, MO, USA). Muse Cell Cycle Kit (Catalog No. MCH100106)
and Muse Annexin V & Dead Cell Kit (Catalog No. MCH100105) were obtained from Milli-
pore Corporation (Hayward, CA, USA). Human Phospho-Kinase Array Kit (catalog Number
ARY003) and Human Apoptosis Array Kit (Catalog Number ARY009) were purchased from
R&D Systems Inc. (Minneapolis, MN, USA). Primary antibodies against cAMP response ele-
ment-binding protein(Creb), P-Creb, and cyclin D1 and secondary antibodies were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Bio-Rad Protein Assay Kit II was
supplied by Bio-Rad (Hercules, CA, USA), and the enhanced chemiluminescent Western blot
detection reagents (Catalog No. RPN2106) were obtained from Amersham Pharmacia Biotech
(Amersham, UK).
Cell lines and cell culture

Cancer cell lines were purchased from American Type Culture Collection (Manassas, VA, USA). The cells were maintained as a monolayer in DMEM or RPMI-1640 medium supplemented with 10% fetal calf serum, 2mM glutamine, 100μg/ml streptomycin, and 100 U/ml penicillin in a humidified atmosphere containing 5% CO₂. Cells in the logarithmic phase were used in the experiments.

MTT viability assay

The determination of cell viability was performed using MTT assay as described previously [14]. Cells were incubated in flat-bottom 96-well plates (6 × 10³ cells/well) overnight. Thereafter, cells were treated with DMSO (0.1%) or an increasing dosage of PD. Following 20, and 44 h of treatment, 20 μl MTT (5 mg/ml) was added to each well and further incubated for 4 h. Cells were then solubilized in 150 μl DMSO. The absorbance reading was obtained using a Dynatech 96-well spectrophotometer (Dynatech Laboratories, Chantilly, VA, USA). The amount of MTT dye reduction was calculated on the basis of the difference between the absorbances at 570 and 630 nm. The cell viability in treated cells was expressed as the amount of dye reduction relative to that in untreated control cells.

Apoptosis assays and cell cycle distribution analysis

The percentage of cells that actively underwent apoptosis was analyzed using annexin V-phycoerythrin-based immunofluorescence according to the user guide of the Muse Annexin V & Dead Cell Kit. The cells were incubated in 6-well plates (2.5 × 10⁵ cells/well) overnight. The cells were then treated with DMSO or PD for 48 h. Adherent and floating cells were collected, washed in cold phosphate-buffered saline (PBS) twice, and then stained with the MuseAnnexin V & Dead Cell reagent. Apoptosis were identified using a Muse Cell Analyzer (Millipore Corporation, Hayward, CA, USA). Cells for cell cycle analysis were washed once with PBS and fixed in 70% cold ethanol for ≥4 h. The fixed cells were then washed twice with PBS, resuspended in 200μl Muse Cell Cycle Reagent, and incubated for30 min at room temperature in the dark. Cell cycle distribution was analyzed by the Muse Cell Analyzer.

Human phosphor-kinase arrays

The phosphorylation profiles of kinases after treatment with PD were analyzed using the Human Phosphor-Kinase Array kit according to the manufacturer's treatment with PD were analyzed using the Human Phosphor. incubated for using a Muse Cell Analyzer (Millipore Corporation, Hayward, CA, USA). Biotinylated detection antibodies, streptavidin-HRP, and chemiluminescent detection reagents were used to detect the phosphorylated cells. The relative expression of specific protein was determined by following the quantification of scanned images.

Western blotting

Western blot assays were performed as described earlier [15]. Cells were treated with DMSO (0.1%) or PD. After 24–48h of treatment, cell lysates were prepared, and equal aliquots of protein extract were electrophoresed by SDS-PAGE. After transferring the lysates to nitrocellulose membranes, blots were blocked with 5% milk protein and were incubated using these primary antibodies for 2h or overnight: P-Creb(Catalog#: 9198, Cell Signaling 1:1000 dilution); Creb (Catalog#: 9197, Cell Signaling 1:1000 dilution); cyclinD1(Catalog#: SC-8396, Santa Cruz 1:500 dilution); cyclinA (Catalog#: SC-596, Santa Cruz 1:500 dilution); cyclinE (Catalog#: SC-247, Santa Cruz 1:1000 dilution). The blots were then reincubated with the corresponding
antibodies for 1h. Blotted proteins were visualized using the enhanced chemiluminescence system, with color markers as molecular size standards. As an internal control for the amount of protein loaded, the same filter was also immunobotted with a monoclonal β-actin (C-4, Santa Cruz 1:1000 dilution) antibody. The protein assay kit was purchased from Bio-Rad (Hercules, CA) and the enhanced chemiluminescent Western blotting detection reagents were purchased from Pharmacia Biotech (Piscataway, NJ).

Statistical analysis
Data were expressed as mean ± SD. Comparisons between the DMSO-treated control cells and PD-treated cells were made using Student’s t test. Comparisons were considered statistically significant when \( P < 0.05 \).

Results

PD inhibits the proliferation of breast cancer cells
The cytotoxicity of PD on breast cancer cells MDA-MB-231 and MCF-7 was determined using MTT assay. The decrease in absorbance in this assay can be due to either a consequence of cell death or reduction in cell proliferation. As shown in Fig 2, PD inhibited the cell proliferation of breast cancer cells MDA-MB-231 and MCF-7 in a dose- and time-dependent manner.

PD induces the S-phase cell cycle arrest of breast cancer cells
To determine the effect of PD on the cell cycle distribution of breast cancer cells MDA-MB-231 and MCF-7, we performed flow cytometry assays after MDA-MB-231 and MCF-7 cells were treated with PD for 24 and 48h. As shown in Fig 3, the treatment of cells with varying concentrations of PD for 24 and 48h resulted in the increased accumulation of cells in the S phase. PD at a concentration of 5 μM (48h) increased the S-phase population from 17.01 ± 1.41% to 20.65 ± 0.77% in MDA-MB-231 cells, and from 15.05 ± 3.53% to 22.05 ± 2.12% in MCF-7 cells. These results indicate that PD can interfere with the cell cycle progression of breast cancer cells.

PD induces the apoptosis of breast cancer cells
To further evaluate the apoptosis-inducing capability of PD in breast cancer cells, breast cancer cells MDA-MB-231 and MCF-7 were treated with various concentrations of PD for 48h. Thereafter, apoptosis was detected by the Muse Cell Analyzer. As shown in Fig 4, PD induced apoptosis in MDA-MB-231 and MCF-7 breast cancer cells in a dose-dependent manner. The percentage of cells undergoing apoptotic cell death increased from 1.93 ± 0.29% to 16.08 ± 4.9% after exposure to 6 μM of PD for 48h in MDA-MB-213 cells and from 2.75 ± 0.11% in the control culture to 64. ± 5.13% after exposure to 6 μM of PD for 48h in MCF-7 cells.

PD decreases the phosphorylation levels of Creb in breast cancer cells
To explore the molecular basis for the anti-proliferation activity of PD in breast cancer cells, human phosphor-kinase arrays were employed to detect the phosphorylation levels of a panel of phospho-kinases after MDA-MB-231 and MCF-7 cancer cells were treated with 5μM PD for 4 and 48h. As shown in Fig 5, the phosphorylation levels of Creb were significantly down-regulated after exposure to 5μM of PD for 4h in MDA-MB-213 cells. Simultaneously, the phosphorylation levels of P38, Erk, and Jun were up-regulated. After the MDA-MB-231 cells were treated with 3 and 5μM PD for 48h, the phosphorylation levels of Creb decreased, and the
Fig 2. Inhibitory effects of PD on the growth of human breast cancer cells. Exponentially growing cells in 96-well plates were continuously treated with the indicated concentrations of PD for 24 and 48 h and then subjected to MTT viability assay. Dose-response curves of PD in (A) MDA-MB-231 and (B) MCF-7 cells 24 or 48 h following treatment. Data are presented as the percentage of DMSO-treated controls (mean ± SD) from three independent experiments. PD, polydatin; MTT, thiazolyl blue tetrazolium bromide; DMSO, dimethylsulfoxide.

https://doi.org/10.1371/journal.pone.0176501.g002
Fig 3. Cell cycle arrest induced by PD in human breast cancer cells. Cells were treated with increasing concentrations of PD. Following 24h and 48h of treatment, cells were labeled with Muse Cell Cycle Reagent and then analyzed by Muse Cell Analyzer. Results indicate the percentage of cells in each phase of the cell cycle. All experiments were performed in duplicate and yielded similar results. (A) Original images of cell cycle distribution in MDA-MB-231 cells are presented. (B) The percentage of cells in S phase is presented as the mean ± SD from three various experiments in MDA-MB-231. *P<0.05, compared with the respective controls. (C) Original images of cell...
The degree of reduction corresponded in a dose-dependent manner. Similar results were observed in the MCF-7 cell lines.

**PI3K/AKT and MAPK pathways are not involved in the effect of PD on cell proliferation**

The human phosphor-kinase arrays showed that the levels of Phospho-protein kinase B9 (AKT), Phospho-P38, and Phospho-Erk increased in breast cancer cells after treatment by PD.
Western Blot analysis showed that the levels of Phospho-AKT and Phospho-Erk increased first and then decreased. At the same time, no obvious change was observed in the level of the AKT and Erk proteins (data not shown). To explore the role of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) pathways in the inhibitory effects of PD on cell proliferation, breast cancer cells MDA-MB-231 and MCF-7 were pre-treated with 100 μM specific PI3K inhibitor wortmannin, ERK1/2 inhibitor PD98059, P38 inhibitor SB203580, and JNK inhibitor SP600125 for 1h. The cells were then treated by PD (2.5, 5μM) for 24 and 48h. As shown in Fig 7, the inhibitory effect of PD on cell proliferation was not affected by the pre-treatment of wortmannin, PD98059, or SP600125. The cell cycle distribution and apoptosis induced by PD were not affected by wortmannin, PD98059, or SP600125, either (data not shown).

PD down-regulates cyclin D1 expression in breast cancer cell lines

To explore the mechanism underlying the effects of PD on S-phase cell cycle arrest, the expression levels of cell cycle-related protein cyclin D1 were examined. The results showed (Fig 8) that the expression of protein cyclin D1 in MDA-MB-231 and MCF-7 cells began to decrease for 4h (Fig 5). Western Blot analysis showed that the levels of Phospho-AKT and Phospho-Erk increased first and then decreased. At the same time, no obvious change was observed in the level of the AKT and Erk proteins (data not shown). To explore the role of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) pathways in the inhibitory effects of PD on cell proliferation, breast cancer cells MDA-MB-231 and MCF-7 were pre-treated with 10μM specific PI3K inhibitor wortmannin, ERK1/2 inhibitor PD98059, P38 inhibitor SB203580, and JNK inhibitor SP600125 for 1h. The cells were then treated by PD (2.5, 5μM) for 24 and 48h. As shown in Fig 7, the inhibitory effect of PD on cell proliferation was not affected by the pre-treatment of wortmannin, SB203580, or SP600125. The cell cycle distribution and apoptosis induced by PD were not affected by wortmannin, SB203580, or SP600125, either (data not shown).
following the treatment with PD for 8h, and continued after 40h of treatment. However, the expression of protein cyclin A didn’t change significantly. Furthermore, the results showed that PD induced the decrease in cyclin D1 in a dose-dependent manner (Fig 8C).

Discussion

As described previously[3], Polygonum cuspidatum, a traditional Chinese medicinal herb commonly used for its roots and rhizomes, has been officially listed in the Pharmacopoeia for a number of years. PD is one of the main effective components of P. cuspidatum. Previously, our study [3] demonstrated that PD could inhibit cell proliferation, induce S-phase cell cycle arrest and apoptosis in human lung cancer cells. In the present study, we evaluated the effect of PD on human breast cancer cell lines MDA-MB-231 and MCF-7, and explored the possible mechanisms. The results showed that PD could effectively inhibit the proliferation and induce the S-phase cell cycle arrest apoptosis in human breast cancer cells MDA-MB-231 and MCF-7.

Creb is a well-characterized transcription factor of the basic leucine zipper family [16]. Creb regulates a number of genes with diverse functions, including proliferation, survival, memory, and learning [17]. Recent studies showed that Creb plays an important role in the development and metastasis of different solid tumors. The level of Creb1 in breast cancer...
patients is elevated and is significantly up-regulated in patients with a poor prognosis, metastatic disease, and nodal involvement [18]. The phosphorylation of Ser133 and/or the nuclear translocation of the transducer of regulated Creb activity co-activators are required for Creb activation [17, 19].

In this study, we found that PD significantly decreased the phosphorylation levels of Creb in a dose-dependent manner. However, the levels of Creb protein were not affected. The results indicated that PD inhibited the activation of Creb by decreasing the phosphorylation of Creb, thus inhibiting the proliferation of breast cancer cells.

In recent studies using a genome wide analysis, Creb was found to regulate approximately 4,000 target genes. The list includes genes that are important for cell cycle control such as cyclinD1 and cyclin A [20]. CyclinD1, an important regulator of cell cycle progression, functions as a transcriptional co-regulator [21]. CyclinD1 levels must be high during the G1 phase to initiate DNA synthesis but must be suppressed to low levels during the S phase for efficient DNA synthesis. To continue cell proliferation, cyclinD1 must be induced once again during the G2 phase [22]. In the present study, we found that the phosphorylation levels of Creb began to decrease after breast cancer cells were treated with PD for 2h, whereas the decrease in the expression level of cyclinD1 occurred at 8h of treatment. Therefore, we speculate that the mechanism underlying the inhibitory effect of PD might be due to inhibition in Creb.
phosphorylation which in turn suppresses the transcription of cyclinD1, and causes cell cycle progression arrest at the S phase, eventually leading to apoptotic death of breast cancer cells.

The PI3K/AKT pathway are implicated in the regulating of proliferation, survival, and death of multiple cells. Recent studies showed that the PI3K/AKT pathway plays a key role in promoting cell proliferation and inhibiting cell apoptosis in the genesis and development of tumors, and abnormalities in this pathway were found in a variety of tumors [23–25]. In the current study, we found that the levels of Phospho-AKT increased in breast cancer cells after treatment by PD. The PI3K inhibitor wortmannin exhibited an insignificant effect on the cell survival, cell cycle, and apoptosis of PD-treated breast cancer cells. These results indicated that the PI3K pathway was not involved in the effect of PD on cell proliferation.

MAPKs include Erk (extracellular signal-regulated protein kinase), JNK (c-Jun N-terminal kinase), and P38. MAPKs are important signaling pathways in the transduction of extracellular stimuli into intracellular responses, and their functions include regulating cell proliferation, differentiation, and apoptosis [26–28]. In this study, Phospho-P38 and Phospho-Erk were increased in breast cancer cells after treatment by PD. However, cell growth inhibition, cell cycle arrest, and apoptosis induced by PD were not affected by Erk inhibitor PD98059 or p38 inhibitor SB203580. These results indicated that the MAPK pathway was not involved in the effect of PD on cell proliferation.

In conclusion, we have performed a preliminary investigation into the inhibitory effect of PD on breast cancer cells. The anti-proliferation effect of PD involves the suppression of cell cycle progression and the induction of apoptosis in human breast cancer cells. The phosphorylation of Creb and cyclinD1 might be involved in the antitumor effect of PD. However, the antitumor effect and toxicity of PD in vivo is unknown. Future studies on the in vivo effect of PD are necessary.

Fig 8. The effect of PD on the expression levels of cell cycle–related protein. Human breast cancer cells were treated with PD for different times (A) or different concentration (D). Expression levels of CyclinD1, CyclinA and CyclinE were detected by western blot analysis and β-actin was used as a control. (B) (C) (E) (F) Cyclin D1 protein bands were quantified by densitometry and the data are presented as the mean ± SD from three experiments. *P<0.05, compared with the respective controls PD, polydatin.
Acknowledgments

The current study was supported by grants from Suzhou Science and Technology Program (SYS201345), Bureau of Public Health of Jiangsu Province (H201413), the second affiliated hospital of Soochow university pre-research project (SDFEYGJ1609) and the second affiliated hospital of Soochow university clinical discipline group project funding (XKQ 2015008).

Author Contributions

Conceptualization: YSZ SJF HCW.

Data curation: SJC JLT FYZ.

Formal analysis: YJ JYX.

Funding acquisition: YSZ.

Investigation: SJC JLT.

Project administration: QS.

Writing – original draft: SJC.

Writing – review & editing: YSZ SJF.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015. 65(2): 87–108. https://doi.org/10.3322/caac.21262 PMID: 25651787

2. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009. 33(5): 315–8. https://doi.org/10.1016/j.canep.2009.10.003 PMID: 19896917

3. Zhang Y, Zhuang Z, Meng Q, Jiao Y, Xu J, Fan S. Polydatin inhibits growth of lung cancer cells by inducing apoptosis and causing cell cycle arrest. Oncol Lett. 2014. 7(1): 295–301 https://doi.org/10.3892/ol.2013.1696 PMID: 24348867

4. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher C Wet al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997. 275(5297): 218–20. PMID: 8985016

5. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002. 8(3): 893–903. PMID: 11895924

6. Rezk YA, Balulad SS, Keller RS, Bennett JA. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol. 2006. 194(5): e23–6. https://doi.org/10.1016/j.ajog.2005.11.030 PMID: 16647892

7. Liu PL, Tsai JR, Charles AL, Hwang JJ, Chou SH, Ping YHet al. Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Mol Nutr Food Res. 2010. 54 Suppl 2: S196–204.

8. Shibata MA, Akao Y, Shibata E, Nozawa Y, Ito T, Mishima Set al. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother Pharmacol. 2007. 60(5): 681–91. https://doi.org/10.1007/s00280-007-0414-y PMID: 17256131

9. Liu HS, Pan CE, Yang W, Liu XM. Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol. 2003. 9(7): 1474–6. https://doi.org/10.3748/wjg.v9.i7.1474 PMID: 12854144

10. Zhou HB, Chen JJ, Wang WX, Cai JT, Du Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol. 2005. 11(2): 280–4. https://doi.org/10.3748/wjg.v11.i2.280 PMID: 15633232

11. Pan MH, Gao JH, Lai CS, et al. Antitumor activity of 3,5,4′-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol Carcinog. 2008. 47(3): 184–96. https://doi.org/10.1002/mc.20352 PMID: 18085528
12. Li T, Fan GX, Wang W, Li T, Yuan YK. Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo. Int Immunopharmacol. 2007. 7(9): 1221–31. https://doi.org/10.1016/j.intimp.2007.05.008 PMID: 17630201

13. Chen JC, Chen Y, Lin JH, Wu JM, Tseng SH. Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound. Anticancer Res. 2006. 26(2A): 1237–45. PMID: 16619530

14. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos M, et al. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene. 1998. 16(23): 3069–82. https://doi.org/10.1038/sj.onc.1202116 PMID: 9662340

15. Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, et al. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene. 2005 Mar 3; 24(10):1749–66. https://doi.org/10.1038/sj.onc.1208327 PMID: 15688034

16. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 1999. 68: 821–61. https://doi.org/10.1146/annurev.biochem.68.1.821 PMID: 10872467

17. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001. 2(8): 599–609. https://doi.org/10.1038/sj.nrb.1004012 PMID: 11483993

18. Chhabra A, Fernando H, Watkins G, Mansel RE, Jiang WG. Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep. 2007. 18(4): 953–8. PMID: 17786359

19. Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell. 1994. 77(6): 799–800. PMID: 8004670

20. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A. 2005. 102(12): 4459–64. https://doi.org/10.1073/pnas.0501076102 PMID: 15753290

21. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007. 6: 24. https://doi.org/10.1186/1476-4598-6-24 PMID: 17407548

22. Yang K, Hitomi M, Stacey DW. Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div. 2006. 1: 32. https://doi.org/10.1186/1747-1028-1-32 PMID: 17176475

23. Roy HK, Olusola BF, Clemens DL, Karolšek WJ, Ratashak A, Lynch HT, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 2002. 23(1): 201–5. PMID: 11756242

24. Xu X, Sakon M, Nagano H, Hiraoka N, Yamamoto H, Hayashi N, et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep. 2004. 11(1): 25–32. PMID: 14654898

25. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004. 10(8): 2846–50. PMID: 15102693

26. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999. 79(1): 143–80. PMID: 9922370

27. Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MT, Bassarova A, Kvalheim G, et al. The mitogen-activated protein kinases (MAPKs) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol. 2006. 102(3): 453–61. https://doi.org/10.1016/j.ygyno.2006.01.034 PMID: 16494928

28. Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat. 2001. 4(4): 253–67. https://doi.org/10.1054/drup.2001.0214 PMID: 11991680